The Latest Breaking News from Novartis AG

Molecular Partners AG (NASDAQ:MOLN) has provided an update regarding the Emergency Use Application (EUA) for ensovibep, a DARPin antiviral therapeutic candidate to treat COVID-19. The Company says that EUA, in review with the FDA, may require additional clinical data to be authorized. Vas Narasimhan also noted that the current omicron wave of SARS-Cov-2,…

Novartis AG (NYSE:NVS) has reported a core EPS of $1.46 in Q1 FY22 compared to $1.38 a year ago, beating the consensus of $1.44. Net income reached $2.2 billion, an increase of 8% or 15% at constant currency rates, mainly driven by higher operating income, partly offset by the loss of Roche Holding (OTC:RHHBY) income.…

The stock market has been experiencing high volatility due to various economic and geopolitical factors. But under these uncertain market conditions investors could add quality mega-cap stocks Novo Nordisk (NVO), Shell (SHEL), Eli Lilly (LLY), Novartis (NVS), and Costco (COST) to their watchlists. Mega-cap stocks are known to endure harsh…

The FDA has granted accelerated approval to Novartis AG's (NYSE: NVS) Vijoice (alpelisib) for patients 2 years of age and older with severe manifestations of PIK3CA-Related Overgrowth Spectrum (PROS) who require systemic therapy.

Novartis AG (NYSE:NVS) announced new long-term data from the Phase 3 ASCLEPIOS 1/2 trials and the ALITHIOS open-label extension of Kesimpta (ofatumumab) in multiple sclerosis. The data demonstrated long-term efficacy and safety of Kesimpta with continued reduced risk of disability worsening in relapsing multiple sclerosis following up to four years of treatment.  Kesimpta…

The European Medicines Agency's (EMA) Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion recommending approval of Novartis AG's (NYSE: NVS) 

The FDA approved Novartis AG's (NYSE:NVS) Pluvicto (lutetium Lu 177 vipivotide tetraxetan) to treat patients with a type of advanced prostate cancer that has spread to other parts of the body. Pluvicto is a targeted radioligand therapy for adult patients who have already undergone other anticancer treatments. The company said it had submitted…

Novartis AG (NYSE:NVS) will suspend capital investments, media advertising, and other promotional activities in Russia but remain committed to providing access to its medicine there. "Novartis condemns the war in Ukraine," it said in a statement, adding that "while we remain committed to providing access to our medicine in Russia, we responsibly…

Novartis AG (NYSE:NVS) announced new data from the completed Phase 3 SPR1NT study of Zolgensma (onasemnogene abeparvovec), a one-time treatment for spinal muscular atrophy (SMA).  The data demonstrated that children with three copies of the SMN2 backup gene who were treated presymptomatically achieved age-appropriate motor milestones, including standing and walking. In addition, a descriptive posthoc…

The New England Journal of Medicine (NEJM) published data from Phase 3 MONALEESA-2 trial of Novartis AG's (NYSE:NVS) Kisqali (ribociclib) plus letrozole demonstrating a statistically significant improvement in overall survival. MONALEESA-2 overall survival data were first presented at the European Society for Medical Oncology Congress in September 2021.  The NEJM publication includes additional analyses substantiating the longest median…

Novartis AG (NYSE: NVS) has